Serina Therapeutics, Inc. (SER) has received approval from the NYSE American to implement its business plan aimed at regaining compliance with listing standards, allowing until July 9, 2027, for the company to meet these requirements. This follows a notice issued in January 2026 regarding non-compliance due to insufficient stockholders’ equity and consecutive losses in three of its last four fiscal years. The company is focused on advancing its SER-252 clinical program for treating advanced Parkinson’s disease.
The acceptance of Serina’s compliance plan is crucial for maintaining its listing status, particularly as it navigates significant financial challenges, including a reported net loss of $19.4 million for 2025. The stock has seen volatility, trading between $1.22 and $7.92 over the past year, and recently closed at $2.12, reflecting a 4.25% increase in after-hours trading.
Investors should monitor Serina’s progress with SER-252 and its financial health closely, as successful execution of their clinical program could be pivotal for future stock performance and compliance with NYSE standards.
Source: nasdaq.com